Binding Database

The following articles (labelled with PubMed ID or TBD) are for your review

PMID

Data

Article Title

Organization

Development of new Malt1 inhibitors and probes.

Leiden University

MALT1 Inhibitors May Potentially Treat Lymphomas and Autoimmune Disorders.

Therachem Research Medilab (India)

Identification of�-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.

Institute of Basic Science (Ibs)

Discovery and optimization of cyclohexane-1,4-diamines as allosteric MALT1 inhibitors.

Astrazeneca

Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.

Chinese Academy of Sciences

Structure-activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease.

Toray Industries

Optimization of the

Novartis Pharma

Discovery of Potent, Highly Selective, and

Novartis Institutes For Biomedical Research

Quinoline and thiazolopyridine allosteric inhibitors of MALT1.

Harvard Medical School

Secondary Metabolites from the Fungus Dictyosporium sp. and Their MALT1 Inhibitory Activities.

National Cancer Institute

Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease.

Janssen Research & Development

Use of Non-Natural Amino Acids for the Design and Synthesis of a Selective, Cell-Permeable MALT1 Activity-Based Probe.

Ku Leuven

Peptide-based covalent inhibitors of MALT1 paracaspase.

Harvard Medical School

N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity.

Novartis Institutes For Biomedical Research